When Van Halen released their groundbreaking self-titled debut album in 1978 everyone was shocked with the incredible guitar playing and were intrigued about how Eddie could play like that. It didn't take long until other guitarists were inspired by his playing and started to play in a similar way. One of them was the Quiet Riot and Ozzy Osbourne guitarist Randy Rhoads, who was compared to Van Halen many times although he was really an incredible player who had many other influences as well, including classical music. But both guitarists had another thing in common, they loved one particular American guitarist. The guitarist that Van Halen and Randy Rhoads loved The guitarist that both Randy Rhoads and Eddie Van Halen loved was the Mountain co-founder, guitarist and singer Leslie West. He not only was inspired by the guitarist but also became his friend. In an interview with Rolling Stone in 2011, he mentioned West as one of his influences. "With Tony (Iommi), it’s the riffs, and the power of the music. And you’ve got people like Ritchie Blackmore (and) Leslie West. Leslie West has this incredible tone in Mountain. And Ritchie Blackmore I liked because of his vibrato bar use on 'Deep Purple in Rock'. Also, they come out with great riffs. I mean, come on, 'Smoke on the Water' is one for the history books," Eddie Van Halen said. Although they were in the music business for decades together, they really became good friends in the 90s when both of them went to rehab. The story was told by West himself in an interview he gave back in 2002 when he performed Mountain's classic "Never In My Life" with Eddie Van Halen. He had already performed "MississippiQueen" with Van Halen in 1995. "I was going to rehab in Milwaukee. I stopped playing for six months. So I met Ed and I introduced myself. After I saw him it got me playing again. He was kicking me up a notch. So I called Randy Bachman. I said, 'how'd you like a rhythm guitar player for nothing?'" He continued: https://youtu.be/qmbYJ0ZRhsU "I just wanted to get on tour. He said great and I went out on the tour, and Eddie and I played every night in the room afterwards and we became friends. He hasn't made any appearances for a long time. (So) he knows how to play 'Never in My Life', one of my songs the right way I forgotten how to play,” Leslie West said. Leslie West was one of Randy Rhoads' favorite guitar players of all time https://www.youtube.com/watch?v=GdYWJeftACo&pp=ygUVdmFuIGhhbGVuIGxlc2xpZSB3ZXN0 The late legendary Ozzy Osbourne and Quiet Riot guitarist Randy Rhoads was also a big fan of Leslie West. He even said in an interview with John Stix in 1981 that the Mountain guitar player was one of his favorites of all time. “Leslie West was one of my all time favorite guitar players. I loved his feel. He used a lot of classical. I can feel he’s really into it when he does those little classical lines. It’s melodic but mean. Beck is also one of my favorites. They’re not idols, but I really like their playing. Beck and Michael Schenker, he’s very classical. (...) Leslie West. Great feel, really moody and powerful. He was one of my favorites.”” Randy Rhoads told John Stix. 11 years older than Rhoads, Leslie West helped to form Mountain in 1969, when Black Sabbath, for example, still hasn’t released their debut album. With songs like “Mississipi Queen”, “Never In My Life” and “Nantucket Sleighride”, they became one of the most influential groups of the 70s. Black Sabbath for example, even ended up being their opening act in the United States in the early 70s when they were still not big. Leslie West and Randy Rhoads had the opportunity to meet each other back in the early 80s. In an interview with Guitar World in 2012, West even said that Randy was prettier than most girls. “We were on tour with them, and that’s where I met Randy and Sharon and we all became friends. All of a sudden, he was gone too quick. I used to think he was prettier than most girls. He played really well; he played a lot of classical lines. I seem to gravitate toward that, so we hit it off,” Leslie West said.The post The guitarist that Van Halen and Randy Rhoads loved appeared first on Rock And Roll Garage.

D!ckhe@d Of The Week! Ep#31 Support DD here: Better value than the ABC. DD's Patreon / itsdangerdan Shout DD a beer https://www.buymeacoffee.com/dangerdan

What’s your take on this passage of scripture? ??‍♂️? “And when ye shall see Jerusalem compassed with armies, then know that the desolation thereof is nigh.” Luke 21:20 https://youtu.be/fd5BjilL8iA?si=4j4O0EzMYY00QPVC

"I had to show what I was going through.” The post The album Joni Mitchell wrote in her “emotionally disturbed period” first appeared on Far Out Magazine.

by Lew Rockwell, Lew Rockwell: Retired American Marine Scott Ritter is not intimidated, and he does not blame the FBI agents themselves.  He reports that they were careful and well-behaved as they searched and raided his cars and home for electronic devices and records on Wednesday.  Ritter, a former UN Nuclear Weapons Inspector and Marine, spoke […]

from The People’s Voice: TRUTH LIVES on at https://sgtreport.tv/

It's so simple yet so stunning! READ MORE...

The U.S. Food and Drug Administration (FDA) declined to approve MDMA, commonly known as ecstasy, as a treatment for post-traumatic stress disorder (PTSD). “Drugmaker Lykos Therapeutics had asked the FDA to approve its MDMA capsules as part of a therapy regimen they argued could be a breakthrough for treating challenging cases of PTSD,” CBS News reports. “The FDA just kneecapped approval of MDMA. This is the highest efficacy / lowest side effect intervention for depression and PTSD ever studied. Helps those suffering get to root cause of trauma. But it’s not a recurring treatment. Against pharma business model,” Calley Means commented. The FDA just kneecapped approval of MDMA. This is the highest efficacy / lowest side effect intervention for depression and PTSD ever studied. Helps those suffering get to root cause of trauma. But it’s not a recurring treatment. Against pharma business model. Outrageous. https://t.co/bAOG6gsvuy pic.twitter.com/Zyl3OrOaZe — Calley Means (@calleymeans) June 5, 2024 Per CBS News: Lykos said the FDA asked for another phase 3 trial to study the safety and efficacy of MDMA. “The FDA request for another study is deeply disappointing, not just for all those who dedicated their lives to this pioneering effort, but principally for the millions of Americans with PTSD, along with their loved ones, who have not seen any new treatment options in over two decades,” Amy Emerson, the CEO of Lykos Therapeutics, said in a release. Emerson said that conducting another phase 3 study, as requested by the FDA, “would take several years” to be done. Phase 3 trials are typically the final and largest stages of clinical studies that drugmakers conduct before seeking approval. Lykos acknowledged that the concerns the FDA raised echoed those that were brought up by an advisory committee earlier this year. That panel had voted by a majority against the application over a number of concerns about the trials it had done so far. The FDA’s rejection of MDMA as a PTSD treatment is a “blow to drug activists and veterans who’ve long campaigned for the psychedelic treatment,” STAT News noted. “The FDA rejected MDMA for PTSD treatment because, and this is seriously the reason, those who were not in the placebo group could tell they were not the placebo group. What a joke. The FDA has approved some of the most evil, damaging ‘medications’ known to man. Someone doesn’t want to lose $$$,” Ashley St. Clair commented. The FDA rejected MDMA for PTSD treatment because, and this is seriously the reason, those who were not in the placebo group could tell they were not the placebo group. What a joke. The FDA has approved some of the most evil, damaging “medications” known to man. Someone doesn’t… https://t.co/A1DxyuBt4s — Ashley St. Clair (@stclairashley) August 11, 2024 STAT News reports: Existing therapies don’t work well for many of the estimated 13 million Americans with PTSD, and no new drug for the disorder has been approved in more than two decades. Several members of MAPS previously said they were expecting FDA approval, and were unprepared for recent questions about data integrity. The ad comm rejection of the evidence from the two trials was a “gut punch,” MAPS executive director Kris Lotlikar said at a public webinar in July. “We’re still fighting a lot of deeply rooted stigma about psychedelics,” he said at the time. “Whatever the outcome, we’re just going to press forward and do whatever we can to make this happen.” Boris Heifets, a neuroscience researcher at Stanford University who studies psychedelics, told STAT he was surprised at the FDA’s decision, adding he’d expected the agency would approve the drug with a requirement for post-approval studies. “PTSD is a major public health issue, and the only way you’ll get any traction is to throw out a little rope for investment in better treatments,” he said. “I was honestly expecting a more positive signal here … now we wonder, will FDA ever approve this stuff?” The FDA, he noted, approved the depression treatment esketamine with far less convincing data than Lykos’ — and he suspects that if a bigger pharmaceutical company had run the trials, MDMA would have won approval. WATCH: